Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Raven, VaxGen deal

VXGN and Raven will merge in a stock deal. Raven stockholders will receive 32 million shares of VXGN valued at $35.5 million based on VXGN's close of $1.11

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE